linjc16/ctgov huggingface dataset:
A Non-invasive Approach to the Assessment of Volume Status in Mechanically Ventilated Septic Patients.

Study Overview
=================
Brief Summary
-----------------
To evaluate the use of sonographic inferior caval vein assessment in mechanically ventilated septic patients. Volume assessment in mechanically ventilated patients with inflammation is of major importance to guide fluid therapy. The researchers investigated whether measurement of caval vein diameter correlates with invasively assessed volume-based hemodynamic parameters.

Conditions
-----------------
Severe Sepsis, Septic Shock

Intervention / Treatment
-----------------
* Procedure: sonographic measurement of inferior caval vein diameter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-90 presence of severe sepsis and septic shock invasive hemodynamic monitoring using the picco system

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: sonographic measurement of inferior caval vein diameter|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Presence of severe sepsis and septic shock, mechanical ventilation
Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE)

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to allow treatment with the sirolimus-eluting Bx VELOCITYTM stent in patients with a serious disease or condition for which there is no generally acceptable alternate treatment available.

Official Title
-----------------
Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: CYPHER Sirolimus-Eluting Coronary Stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or non-pregnant female patient minimum 18 years of age There is no alternative treatment for this patient as determined by the treating physician and an uninvolved cardiac surgeon; Target lesion is 2.50mm and 3.50mm in diameter (visual estimate); Target lesion is 45mm in length (visual estimate), treated with a maximum of three 18 mm stents; Exclusion Criteria: There is currently another method of treatment for the patient, including coronary artery bypass surgery (CABG) or brachytherapy; The study target lesion has definite or possible thrombus present by angiographic criteria.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>CYPHER Sirolimus-Eluting Coronary Stent | Device: CYPHER Sirolimus-Eluting Coronary Stent<br>* CYPHER Sirolimus-Eluting Coronary Stent<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint of this study is a composite of Target Vessel Failure (TVF) defined as target vessel revascularization, myocardial infarction or cardiac death at 30 days, 6mo, 12mo, 2, 3, 4, and 5 years. |  | 30 days, 6mo, 12mo, 2, 3, 4, and 5 years |
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy

Study Overview
=================
Brief Summary
-----------------
The anti-hinge region antibodies would be a relevant biomarker of IgA nephropathy. Beyond a prognostic value (which could increase the risk of Renal Absolute), the longitudinal monitoring for these antibodies could be of interest: (1) in the monitoring of patients (in place including a possible repetition renal biopsy); (2) to guide treatment decisions and (3) in clinical research, as an outcome (in substitution for the occurrence of kidney failure) in therapeutic trials IgA nephropathy. This research project constitutes the first step in validating these antibodies biomarker of IgA nephropathy and its main objective is to study the performance of the blood levels of anti-hinge region antibodies in the diagnosis of progressive forms of histologically IgA nephropathy as defined by the Renal Risk Absolute. The secondary objectives of this project are to establish a bio-collection that will allow us to search for other prognostic factors (genetic, cellular and serum) of IgA nephropathy and to evaluate the performance of Renal Absolute risk by integrating Oxford score, the new international histological classification.

Official Title
-----------------
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy

Conditions
-----------------
IgA Nephropathy

Intervention / Treatment
-----------------
* Biological: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major Patient Diagnosis of a primitive form of IgA nephropathy histologically proven Exclusion Criteria: Suspicion of secondary IgA nephropathy forms Less than 5 glomeruli present on renal biopsy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: patient with primitive form of IgA nephropathy<br> | Biological: blood sample<br>* dosage of anti-hinge region antibodies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum concentration of anti-hinge region antibodies (mg/ml) |  | Baseline |
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of the trial is to find some biomarkers to predict the efficacy of Atezolizumab plus etoposide and platinum based chemotherapy as the first line treatment in extensive stage small cell lung cancer. Mainly observe the patient's progression free survival time after treatment.

Official Title
-----------------
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy

Conditions
-----------------
Extensive Stage Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: First line EC/EP+Atezolizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18， Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy Exclusion Criteria: - Patients with contraindication of chemotherapy Pregnant or breast feeding women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression free survival | April 2019- July 2021 | 
| OS | Overall survival | April 2019- July 2021 |
Treatment of Early Systemic Sclerosis by Bosentan

Study Overview
=================
Brief Summary
-----------------
Systemic sclerosis (ssc) is characterised by extensive tissue fibrosis. Using drugs that are capable of inhibiting fibroblast activity may be beneficial if administrered early in the disease course. Thirty adult patients with early SSc will be treated with the endothelin-1 antagonist bosentan for 6 months.Disease progression will be assessed.

Detailed Description
-----------------
Systemic sclerosis (SSc) is characterised by obliterative vasculopathy and extensive fibrosis. The accumulation of extracellular components in the extracellular matrix is mostly due to increased activity og tissue fibroblasts. The proliferation and hyperactivity of the fibroblasts may be caused by enhanced production of several cytokins, among them endothelin-1.The activity of endothelin-1 has been shown to be increased both in the circulation and within skin lesions. Endothelin-1 has several distinct properties, among them profibrotic activity, inflammatory and vasoconstriction.Thus, the actions induced by endothelin-1 may be a potensial target for the therapy of SSc. Thirty patients with early SSc, that is of less than 12 months duration will be offered six months of treatment with the oral dual endothelin-1 antagonist bosentan. Assessment of disease progression will be performed at 3, 6, 9. 12 and 24 months using clinical, histological and immunohistochemical methods.

Conditions
-----------------
Systemic Sclerosis (Scleroderma)

Intervention / Treatment
-----------------
* Drug: bosentan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Early systemic sclerosis Exclusion Criteria: Age > 70 or < 18 Pregnancy Nursing HIV Hb < 8.5 g/l Systolic blood pressure < 85 mmHg Lack of compliance Liver disease Hypersensitivity to bosentan Concurrent us of glibenclamide, ciclosporine A or tacrolimus -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: bosentan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall clinical progression |  |  | 
| Degree of deposition of ET-1 in skin |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of extradermatological manifestations |  |  | 
| Quality of life |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Scleroderma, Fibrosis, Therapy, Bosentan, Endothelin-1
Effect of Multiple Subcisions on Rolling Acne Scars

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find out whether the use of multiple subcisions over several visits will improve the appearance of rolling acne scars compared to no treatment. This study was a pilot study designed to determine feasibility of this procedure.

Official Title
-----------------
Pilot Split Face Randomized, Evaluator Blinded Study on the Effect of Multiple Subcisions on Rolling Acne Scars

Conditions
-----------------
Acne Scars

Intervention / Treatment
-----------------
* Procedure: Multiple Subcision


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 to 65 Have bilateral rolling acne scars on each side of their face No active or ongoing acne. The subjects are in good health The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator. Exclusion Criteria: Under 18 years of age Pregnancy or Lactation Subjects who are unable to understand the protocol or to give informed consent Subjects with mental illness Recent Accutane use in the past 6 months Subjects prone to hypertrophic and keloidal scarring Subjects reporting any blood diseases (HIV, Hepatitis, etc.) Subjects reporting a history of Herpes (oral or genital)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Multiple Subcision<br>Subjects will receive multiple subcision treatments to their randomized side of the face 5 times total spaced 4 weeks apart. | Procedure: Multiple Subcision<br>* At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.<br>|
| No Intervention: Control<br>Subjects will receive no intervention control on the other side of the face. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in acne scarring compared to baseline after treatments | The change in acne scarring is measured using a quantitative global scarring grading system to compare baseline to the treatment. | Baseline and 36 weeks |
BIOmarkers of Dyspnea IN Emergency Room

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.

Detailed Description
-----------------
In emergency department shortness of breath (SOB)is a common symptom and its cause is not easy to be identified. The risk stratifying remains a challenge, Prognostic value of biomarkers might be helpful.

Official Title
-----------------
Prognostic Value of Novel Biomarkers in Patients With Shortness of Breath Attending an Emergency Department

Conditions
-----------------
Severe Dyspnea, CAPD, AE COPD, Acute Heart Failure, Pulmonary Embolism

Intervention / Treatment
-----------------
* Other: Prognostic value of Biomarkers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: tachypnea > 25 /min or Pa02 < 70 mmHg or SpO2 < 93% diagnosis suspected: CAP, PE,EACOPD, AHF Exclusion Criteria: other cause of dyspnea, unreachable on Day 30

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute dyspnea in ED<br>Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD) | Other: Prognostic value of Biomarkers<br>* Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients<br>* Other names: Prognostic value;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prognostic value of PCT, MR proADM, Mr pro ANP, Copeptin and pro endothelin in SOB | all cause mortality or Intensive Care Unit(ICU) admission from inclusion to Day 30 | at Day 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| establish the diagnostic value of PCT and MR pro ANP | Confirm the diagnostic value of PCT and it's level in sepsis and MR pro ANP in Heart failure | at admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyspnea, Mortality
Baseline Cardiovascular Measurements in Pediatric Spinal Cord Injury

Study Overview
=================
Brief Summary
-----------------
Following spinal cord injury (SCI), the body loses normal control of blood pressure and heart rate, and there is a risk of sudden and dangerous increases in blood pressure, namely, autonomic dysreflexia (AD). It is important to be aware of baseline blood pressures and heart rates in individuals in order to detect AD. However, baseline values vary in developing children, and may be more variable in children with SCI. Thus, the objective of this study is to determine baseline blood pressure and heart rate measurements in children with SCI during rest and during urodynamic testing. The investigators hypothesize that 1) blood pressures will increase with increasing age and body mass index; 2) heart rate will decrease with increasing age; 3) blood pressures will increase with increase in bladder filling; 4) blood pressures will increase will increase with increasing duration of injury.

Official Title
-----------------
Cardiovascular Measurements at Baseline and During Cystometry in Pediatric Spinal Cord Injury

Conditions
-----------------
Spinal Cord Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children and adolescents with spinal cord injury age 18 years or younger Exclusion Criteria: known history of hypertension, cardiac, renal, or thyroid disease recent surgical procedure less than 2 weeks prior to admission or visit fever or signs of active infection or inflammation

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Inpatient<br>Youths admitted for inpatient rehabilitation training | |
| Outpatient<br>Youths visiting outpatient clinics | |
| Urodynamic study<br>Youths who undergo scheduled urodynamic study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure readings |  | at regularly scheduled medical appointments | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pediatric spinal cord injury, blood pressure, heart rate, baseline
The Role of Lung Ultrasound During Perioperative Evaluation

Study Overview
=================
Brief Summary
-----------------
Accurate pre-operative lung assessment is important to decide the most appropriate anesthesia plan. Until now, chest X-ray is considered the standard of care for lung assessment during perioperative evaluation. However, lung ultrasound is a rapid, simple, non-invasive, radiation-free imaging modality and can be used as an alternative to chest radiography for the diagnosis and follow-up of various lung diseases. Moreover, the decreased radiation exposure represents a considerable improvement in patient safety. Consequently, we decided to compare the data obtained from the lung ultrasound and the chest X-ray.

Official Title
-----------------
Comparison of Lung Ultrasound Assessment and Chest Radiography During Perioperative Evaluation: a Prospective Study

Conditions
-----------------
Lung Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: Lung ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients undergoing elective general surgery; age >18 years; ability to provide written consent; use of Chest radiography during the preoperative evaluation. Exclusion Criteria: age < than 18 year; pregnant patients; not use of Chest radiography during the preoperative evaluation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lung ultrasonography<br> | Diagnostic Test: Lung ultrasonography<br>* Lung ultrasound scan during preoperative anaesthesia consultation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance comparison of lung ultrasonography and chest x-ray in the detection of pleural effusion, consolidation, alveolar- interstitial syndrome. | The primary objective of this project is to evaluate the possible correlation between the data obtained from the ultrasound scan and the data obtained from the chest X-ray. | during preoperative anaesthesia consultation |